{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:07:11Z","timestamp":1791875231658,"version":"4.3.4"},"reference-count":71,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre, Poland","doi-asserted-by":"publisher","award":["2018\/31\/B\/NZ6\/02017"],"award-info":[{"award-number":["2018\/31\/B\/NZ6\/02017"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Ebselen is a low-molecular-weight organoselenium compound that has been broadly studied for its antioxidant, anti-inflammatory, and cytoprotective properties. These advantageous properties were initially associated with mimicking the activity of selenoprotein glutathione peroxidase, but the biomedical impact of this compound appear to be far more complex. Ebselen serves as a substrate or inhibitor with multiple protein\/enzyme targets, whereas inhibition typically originates from the covalent modification of cysteine residues by opening the benzisoselenazolone ring and S\u2013Se bond formation. The inhibition of enzymes of various classes and origins has been associated with substantial antimicrobial potential among other activities. In this contribution, we summarize the current state of the art regarding the antibacterial activity of ebselen. This activity, alone and in combination with commercial pharmaceuticals, against pathogens, including those resistant to drugs, is presented, together with the molecular mechanism behind the reactivity. The specific inactivation of thioredoxin reductase, bacterial toxins, and other resistance factors is considered to have certain therapeutic implications. Synergistic action and sensitization to common antibiotics assisted with the use of ebselen appear to be promising directions in the treatment of persistent infections.<\/jats:p>","DOI":"10.3390\/ijms24021610","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T05:09:32Z","timestamp":1673586572000},"page":"1610","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Antibacterial Activity of Ebselen"],"prefix":"10.3390","volume":"24","author":[{"given":"Marta","family":"Ma\u015blanka","sequence":"first","affiliation":[{"name":"Department of Bioorganic Chemistry, Wroc\u0142aw University of Science and Technology, Wybrze\u017ce Wyspia\u0144skiego 27, 50-370 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-1371","authenticated-orcid":false,"given":"Artur","family":"Mucha","sequence":"additional","affiliation":[{"name":"Department of Bioorganic Chemistry, Wroc\u0142aw University of Science and Technology, Wybrze\u017ce Wyspia\u0144skiego 27, 50-370 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"ref_1","unstructured":"Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet, 399, 629\u2013655."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.7150\/thno.56205","article-title":"Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1007\/s11033-014-3417-x","article-title":"Ebselen, a promising antioxidant drug: Mechanisms of action and targets of biological pathways","volume":"41","author":"Azad","year":"2014","journal-title":"Mol. Biol. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1017\/erm.2021.14","article-title":"Ebselen, a multi-target compound: Its effects on biological processes and diseases","volume":"23","author":"Lu","year":"2021","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Santi, C., Scimmi, C., and Sancineto, L. (2021). Ebselen and analogues: Pharmacological properties and synthetic strategies for their preparation. Molecules, 26.","DOI":"10.3390\/molecules26144230"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00204-021-03003-5","article-title":"Toxicology and pharmacology of synthetic organoselenium compounds: An update","volume":"95","author":"Nogueira","year":"2021","journal-title":"Arch. Toxicol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1021\/acs.jmedchem.9b01152","article-title":"Development and therapeutic potential of selenazo compounds","volume":"63","author":"Ruberte","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.freeradbiomed.2020.06.032","article-title":"Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections","volume":"156","author":"Sies","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1128\/AAC.33.8.1388","article-title":"Susceptibility of methicillin-resistant Staphylococcus aureus to the selenium-containing compound 2-phenyl-1,2-benzoisoselenazol-3(2H)-one (PZ51)","volume":"33","author":"Nozawa","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.2174\/1381612821666150506154434","article-title":"Repurposing non-antimicrobial drugs and clinical molecules to treat bacterial infections","volume":"21","author":"Younis","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Thangamani, S., Younis, W., and Seleem, M.N. (2015). Repurposing clinical molecule ebselen to combat drug resistant pathogens. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0133877"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11596","DOI":"10.1038\/srep11596","article-title":"Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections","volume":"5","author":"Thangamani","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"AbdelKhalek, A., Abutaleb, N.S., Mohammad, H., and Seleem, M.N. (2018). Repurposing ebselen for decolonization of vancomycin-resistant enterococci (VRE). PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0199710"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Mohammad, H., Abutaleb, N.S., Dieterly, A.M., Lyle, L.T., and Seleem, M.N. (2021). Evaluation of ebselen in resolving a methicillin-resistant Staphylococcus aureus infection of pressure ulcers in obese and diabetic mice. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247508"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jgar.2021.09.003","article-title":"In vitro activity of non-antibiotic drugs against Staphylococcus aureus clinical strains","volume":"27","author":"Boyd","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41579-022-00682-4","article-title":"Tolerance and resistance of microbial biofilms","volume":"20","author":"Ciofu","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1128\/AAC.00377-16","article-title":"Screening a commercial library of pharmacologically active small molecules against Staphylococcus aureus biofilms","volume":"60","author":"Torres","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/2212796816666220330090107","article-title":"Ebselen\u2019s potential to inhibit planktonic and biofilm growth of Neisseria mucosa","volume":"16","author":"Shaikh","year":"2022","journal-title":"Curr. Chem. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jconrel.2022.05.044","article-title":"Antibiotics-free nanoparticles eradicate Helicobacter pylori biofilms and intracellular bacteria","volume":"348","author":"Zou","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1096\/fj.12-223305","article-title":"Inhibition of bacterial thioredoxin reductase: An antibiotic mechanism targeting bacteria lacking glutathione","volume":"27","author":"Lu","year":"2013","journal-title":"FASEB J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.freeradbiomed.2013.07.036","article-title":"The thioredoxin antioxidant system","volume":"66","author":"Lu","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"663481","DOI":"10.3389\/fmicb.2021.663481","article-title":"Thioredoxin reductase is a valid target for antimicrobial therapeutic development against gram-positive bacteria","volume":"12","author":"Felix","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.freeradbiomed.2018.05.081","article-title":"Selenocysteine in mammalian thioredoxin reductase and application of ebselen as a therapeutic","volume":"127","author":"Ren","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.3389\/fmicb.2019.03016","article-title":"Topical therapeutic efficacy of ebselen against multidrug-resistant Staphylococcus aureus LT-1 targeting thioredoxin reductase","volume":"10","author":"Dong","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bbagen.2016.03.013","article-title":"Ebselen and analogs as inhibitors of Bacillus anthracis thioredoxin reductase and bactericidal antibacterials targeting Bacillus species, Staphylococcus aureus and Mycobacterium tuberculosis","volume":"1860","author":"Gustafsson","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s00203-019-01729-6","article-title":"Understanding the survival mechanisms of Deinococcus radiodurans against oxidative stress by targeting thioredoxin reductase redox system","volume":"202","author":"Maqbool","year":"2020","journal-title":"Arch. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"127070","DOI":"10.1016\/j.micres.2022.127070","article-title":"Redox status and metabolomic profiling of thioredoxin reductase inhibitors and 4 kGy ionizing radiation-exposed Deinococcus radiodurans","volume":"261","author":"Sudharsan","year":"2022","journal-title":"Microbiol. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"104697","DOI":"10.1016\/j.jprot.2022.104697","article-title":"Proteomic profiling of Deinococcus radiodurans with response to thioredoxin reductase inhibitor and ionizing radiation treatment","volume":"267","author":"Sudharsan","year":"2022","journal-title":"J. Proteom."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.15252\/emmm.201707661","article-title":"Synergistic antibacterial effect of silver and ebselen against multidrug-resistant Gram-negative bacterial infections","volume":"9","author":"Zou","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1111\/jcmm.15920","article-title":"Depletion of multidrug-resistant uropathogenic Escherichia coli BC1 by ebselen and silver ion","volume":"24","author":"Wang","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1039\/d0mt00091d","article-title":"Synergistic therapeutic efficacy of ebselen and silver ions against multidrug-resistant Acinetobacter baumannii-induced urinary tract infections","volume":"12","author":"Dong","year":"2020","journal-title":"Metallomics"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"963901","DOI":"10.3389\/fmicb.2022.963901","article-title":"The assessment on synergistic activity of ebselen and silver ion against Yersinia pseudotuberculosis","volume":"13","author":"Dong","year":"2022","journal-title":"Front. Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"38483","DOI":"10.1021\/acsami.2c08845","article-title":"Enzyme-responsive COF-based thiol-targeting nanoinhibitor for curing bacterial infections","volume":"14","author":"Wang","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1080\/21691401.2019.1648278","article-title":"Characterization of synergistic antibacterial effect of silver nanoparticles and ebselen","volume":"47","author":"Chen","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0891-5849(93)90028-S","article-title":"Ebselen. A selenoorganic compound as glutathione peroxidase mimic","volume":"14","author":"Sies","year":"1993","journal-title":"Free Radic. Biol. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jbt.20189","article-title":"Evaluation of the antimicrobial activity of ebselen: Role of the yeast plasma membrane H+-ATPase","volume":"21","author":"Chan","year":"2007","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"306ra148","DOI":"10.1126\/scitranslmed.aac9103","article-title":"A small-molecule antivirulence agent for treating Clostridium difficile infection","volume":"7","author":"Bender","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","article-title":"Clostridioides difficile Infection Working Group. Trends in U.S. burden of Clostridioides difficile infection and outcomes","volume":"382","author":"Guh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mib.2016.11.006","article-title":"The emerging metabolic view of Clostridium difficile pathogenesis","volume":"35","author":"Hryckowian","year":"2017","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100005","DOI":"10.1016\/j.xcrm.2020.100005","article-title":"The clinical drug ebselen attenuates inflammation and promotes microbiome recovery in mice after antibiotic treatment for CDI","volume":"1","author":"Garland","year":"2020","journal-title":"Cell. Rep. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"370tc2","DOI":"10.1126\/scitranslmed.aad8926","article-title":"Comment on \u201cA small-molecule antivirulence agent for treating Clostridium difficile infection\u201d","volume":"8","author":"Beilhartz","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e0044821","DOI":"10.1128\/Spectrum.00448-21","article-title":"Ebselen not only inhibits Clostridioides difficile toxins but displays redox-associated cellular killing","volume":"9","author":"Marreddy","year":"2021","journal-title":"Microbiol. Spectr."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8125","DOI":"10.1021\/acs.jmedchem.6b00986","article-title":"1,2-Benzisoselenazol-3(2H)-one derivatives as a new class of bacterial urease inhibitors","volume":"59","author":"Macegoniuk","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jare.2018.05.010","article-title":"Ureases: Historical aspects, catalytic, and non-catalytic properties\u2014A review","volume":"13","author":"Kappaun","year":"2018","journal-title":"J. Adv. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00775-020-01808-w","article-title":"The structure-based reaction mechanism of urease, a nickel dependent enzyme: Tale of a long debate","volume":"25","author":"Mazzei","year":"2020","journal-title":"JBIC J. Biol. Inorg. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"12807","DOI":"10.1038\/s41598-017-12718-4","article-title":"Dissecting the mycobacterial cell envelope and defining the composition of the native mycomembrane","volume":"7","author":"Chiaradia","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1038\/ncomms3748","article-title":"Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen","volume":"4","author":"Favrot","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/s41467-021-23313-7","article-title":"Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives","volume":"12","author":"Amporndanai","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11349","DOI":"10.1021\/acs.jpcb.0c08192","article-title":"Exploring the catalytic reaction of cysteine proteases","volume":"124","author":"Oanca","year":"2020","journal-title":"J. Phys. Chem. B"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"25031","DOI":"10.1074\/jbc.M114.582445","article-title":"Inactivation of the Mycobacterium tuberculosis antigen 85 complex by covalent, allosteric inhibitors","volume":"289","author":"Favrot","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1021\/acsinfecdis.7b00003","article-title":"Exploring covalent allosteric inhibition of antigen 85C from Mycobacterium tuberculosis by ebselen derivatives","volume":"3","author":"Goins","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1111\/febs.16066","article-title":"LD-transpeptidases: The great unknown among the peptidoglycan cross-linkers","volume":"289","author":"Aliashkevich","year":"2022","journal-title":"FEBS J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"10214","DOI":"10.1039\/C9CC04145A","article-title":"Targeting the Mycobacterium tuberculosis transpeptidase LdtMt2 with cysteine-reactive inhibitors including ebselen","volume":"55","author":"Lohans","year":"2019","journal-title":"Chem. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00044-020-02580-x","article-title":"New Delhi metallo-\u03b2-lactamase-1 inhibitors for combating antibiotic drug resistance: Recent developments","volume":"29","author":"Grewal","year":"2020","journal-title":"Med. Chem. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1021\/acsinfecdis.8b00247","article-title":"Ten years with New Delhi metallo-\u03b2-lactamase-1 (NDM-1): From structural insights to inhibitor design","volume":"5","author":"Linciano","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1039\/C5CC02594J","article-title":"Ebselen as a potent covalent inhibitor of New Delhi metallo-\u03b2-lactamase (NDM-1)","volume":"51","author":"Chiou","year":"2015","journal-title":"Chem. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejmech.2018.06.007","article-title":"Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1","volume":"155","author":"Jin","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1039\/C8CC01067F","article-title":"A protein structure-guided covalent scaffold selectively targets the B1 and B2 subclass metallo-\u03b2-lactamases","volume":"54","author":"Chen","year":"2018","journal-title":"Chem. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bioorg.2018.11.035","article-title":"Ebsulfur as a potent scaffold for inhibition and labelling of New Delhi metallo-\u03b2-lactamase-1 in vitro and in vivo","volume":"84","author":"Su","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"103873","DOI":"10.1016\/j.bioorg.2020.103873","article-title":"Bioisosteric investigation of ebselen: Synthesis and in vitro characterization of 1,2-benzisothiazol-3(2H)-one derivatives as potent New Delhi metallo-\u03b2-lactamase inhibitors","volume":"100","author":"Jin","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1248\/cpb.56.1423","article-title":"New organoselenium compounds active against pathogenic bacteria, fungi and viruses","volume":"56","author":"Piasecki","year":"2008","journal-title":"Chem. Pharm. Bull."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"546","DOI":"10.24820\/ark.5550190.p009.797","article-title":"Synthesis of new alkylated and methoxylated analogues of ebselen with antiviral and antimicrobial properties","volume":"2017","author":"Kaleta","year":"2017","journal-title":"Arkivoc"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"103286","DOI":"10.1016\/j.bioorg.2019.103286","article-title":"Ebselen bearing polar functionality: Identification of potent antibacterial agents against multidrug-resistant Gram-negative bacteria","volume":"93","author":"Chen","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1016\/j.bmc.2016.03.060","article-title":"Development of ebsulfur analogues as potent antibacterials against methicillin-resistant Staphylococcus aureus","volume":"24","author":"Ngo","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1021\/acsinfecdis.1c00045","article-title":"Inhibition of Pseudomonas aeruginosa alginate synthesis by ebselen oxide and its analogues","volume":"7","author":"Kim","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Mancuso, G., Midiri, A., Gerace, E., and Biondo, C. (2021). Bacterial antibiotic resistance: The most critical pathogens. Pathogens, 10.","DOI":"10.3390\/pathogens10101310"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/jam.14478","article-title":"Recent updates on drug resistance in Mycobacterium tuberculosis","volume":"128","author":"Singh","year":"2020","journal-title":"J. Appl. Microbiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000015908","article-title":"Ebselen in acute middle cerebral artery occlusion: A placebo-controlled, double-blind clinical trial","volume":"9","author":"Ogawa","year":"1999","journal-title":"Cerebrovasc. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/01.STR.29.1.12","article-title":"Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial. Ebselen Study Group","volume":"29","author":"Yamaguchi","year":"1998","journal-title":"Stroke"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0140-6736(17)31791-9","article-title":"Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"390","author":"Kil","year":"2017","journal-title":"Lancet"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1610\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:05:17Z","timestamp":1760119517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":71,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24021610"],"URL":"https:\/\/doi.org\/10.3390\/ijms24021610","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}